News coverage about GlycoMimetics (NASDAQ:GLYC) has trended somewhat positive on Friday, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GlycoMimetics earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.361124685931 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Several analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of GlycoMimetics from a “hold” rating to a “sell” rating in a research note on Monday, August 7th. BidaskClub raised shares of GlycoMimetics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $21.00 price target on shares of GlycoMimetics in a research note on Wednesday. Stifel Nicolaus reaffirmed a “buy” rating and set a $17.00 price target (up previously from $13.00) on shares of GlycoMimetics in a research note on Friday, August 4th. Finally, ValuEngine raised shares of GlycoMimetics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $14.20.

GlycoMimetics (NASDAQ GLYC) traded down 1.06% during mid-day trading on Friday, hitting $13.02. 191,881 shares of the stock traded hands. The stock’s market cap is $426.05 million. The stock has a 50-day moving average price of $12.34 and a 200-day moving average price of $9.79. GlycoMimetics has a 12 month low of $3.82 and a 12 month high of $16.94.

GlycoMimetics (NASDAQ:GLYC) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.30) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.07. On average, equities analysts forecast that GlycoMimetics will post ($1.22) earnings per share for the current year.

In other GlycoMimetics news, SVP Helen M. Thackray sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $13.00, for a total value of $26,000.00. Following the completion of the transaction, the senior vice president now owns 150,615 shares of the company’s stock, valued at approximately $1,957,995. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 43.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect GlycoMimetics (GLYC) Stock Price” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at

GlycoMimetics Company Profile

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Insider Buying and Selling by Quarter for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.